Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy

Kazuyuki Matsushita, Hideaki Shimada, Yasuji Ueda, Makoto Inoue, Mamoru Hasegawa, Takeshi Tomonaga, Hisahiro Matsubara, Fumio Nomura

Kazuyuki Matsushita, Fumio Nomura, Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
Hideaki Shimada, Department of Surgery, School of Medicine, Toho University, Tokyo 143-8541, Japan
Yasuji Ueda, Makoto Inoue, Mamoru Hasegawa, DNAVEC Corporation, 6 Ohkubo, Tsukuba City, Ibaraki 300-2611, Japan
Takeshi Tomonaga, Proteome Research Center, Proteome Research Project, National Institute of Biomedical Innovation, Osaka 567-0085, Japan
Hisahiro Matsubara, Department of Frontier Surgery, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan

Author contributions: Matsushita K designed the research; Matsushita K, Ueda Y and Inoue M performed the research; Shimada H, Tomonaga T, Hasegawa M, Matsubara H and Nomura F contributed new reagents/analytic tools and scientific discussions; Matsushita K analyzed the data and wrote the paper.

Supported by In part by the 21st Century COE (Center Of Excellence) Programs to Dr. Takenori Ochiai and by a Grant-in-Aid 18591453 to K.M from the Ministry of Education, Science, Sports and Culture of Japan

Correspondence to: Kazuyuki Matsushita, MD, PhD, Associate Professor, Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba 260-8670, Japan. kmatsu@faculty.chiba-u.jp
Telephone: +81-43-2227171 Fax: +81-43-2262169
Received: October 22, 2013 Revised: December 14, 2013 Accepted: January 19, 2014 Published online: April 21, 2014

Abstract

AIM: To investigate a novel therapeutic strategy to target and suppress c-myc in human cancers using far up stream element (FUSE)-binding protein-interacting repressor (FIR).

METHODS: Endogenous c-Myc suppression and apoptosis induction by a transient FIR-expressing vector was examined in vivo via a HA-tagged FIR (HA-FIR) expression vector. A fusion gene-deficient, non-transmissible, Sendai virus (SeV) vector encoding FIR cDNA, SeV/dF/FIR, was prepared. SeV/dF/FIR was examined for its gene transduction efficiency, viral dose dependency of antitumor effect and apoptosis induction in HeLa (cervical squamous cell carcinoma) cells and SW480 (colon adenocarcinoma) cells. Antitumor efficacy in a mouse xenograft model was also examined. The molecular mechanism of the anti-tumor effect and c-Myc suppression by SeV/dF/FIR was examined using spliceostatin A (SSA), a SAP155 inhibitor, or SAP155 siRNA which induce c-Myc by increasing FIRΔexon2 in HeLa cells.

RESULTS: FIR was found to repress c-myc transcription and in turn the overexpression of FIR drove apoptosis through c-myc suppression. Thus, FIR expressing vectors are potentially applicable for cancer therapy. FIR is alternatively spliced by SAP155 in cancer cells lacking the transcriptional repression domain within exon 2 (FIRΔexon2), counteracting FIR for c-Myc protein expression. Furthermore, FIR forms a complex with SAP155 and inhibits mutual well-established functions. Thus, both the valuable effects and side effects of exogenous FIR stimuli should be tested for future clinical application. SeV/dF/FIR, a cytoplasmic RNA virus, was successfully prepared and showed highly efficient gene transduction in in vivo experiments. Furthermore, in nude mouse tumor xenograft models, SeV/dF/FIR displayed high antitumor efficiency against human cancer cells. SeV/dF/FIR suppressed SSA-activated c-Myc. SAP155 siRNA, potentially produces FIRΔexon2, and led to c-Myc overexpression with phosphorylation at Ser62. HA-FIR suppressed endogenous c-Myc expression and induced apoptosis in HeLa and SW480 cells. A c-myc transcriptional suppressor FIR expressing SeV/dF/FIR showed high gene transduction efficiency with significant antitumor effects and apoptosis induction in HeLa and SW480 cells.

CONCLUSION: SeV/dF/FIR showed strong tumor growth
suppression with no significant side effects in an animal xenograft model, thus SeV/dF/FIR is potentially applicable for future clinical cancer treatment.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Cancer gene therapy; c-myc suppressor; Far up stream element-binding protein-interacting repressor; Sendai virus vector

Core tip: The authors performed in vivo experiments and included an animal model to examine the Sendai virus/dF/FIR expression in a FUSE-dependent manner which is pivotal for future clinical use.

Matsushita K, Shimada H, Ueda Y, Inoue M, Hasegawa M, Tomonaga T, Matsubara H, Nomura F. Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer gene therapy to minimize side effects for clinical use.

INTRODUCTION

C-Myc plays an essential role in cell proliferation and tumorigenesis. c-myc activation was also shown to be required for skin epidermal and pancreatic beta-cell tumor maintenance in c-MYC-ER/TAM transgenic mice[1]. High c-myc expression level in colorectal cancer tissues was associated with poor long-term survival of colorectal cancer patients[2]. The far up stream element (FUSE) is a sequence required for correct expression of the human c-myc gene[3]. The FUSE is located at 1.5 kb upstream of c-myc promoter P1, and binds the FUSE binding protein (FBP), a transcription factor which stimulates c-myc expression in a FUSE-dependent manner[4]. Yeast two-hybrid analysis revealed that FBP binds to a protein that has transcriptional inhibitory activity termed the FBP interacting repressor (FIR). FIR interacts with the central DNA binding domain of FBP[5]. Recently, FIR was found to engage the TFIIH/p89/XPB helicase and repress c-myc transcription by delaying promoter escape[6]. Furthermore, exogenous FIR expression represses endogenous c-myc transcription, and drives apoptosis due to the decrease in c-Myc[7]. Although these observations indicate that cancer therapies targeting c-myc suppression by FIR may be a useful strategy, the mechanism of the antitumor effect of FIR should be determined in detail prior to clinical testing. For example, first, FIR is alternatively spliced in colorectal cancer lacking the transcriptional repression domain within exon 2 (FIRΔexon2)[7]. Second, FIR and FIRΔexon2 form a homo- or hetero-dimer, which complexes with SAP155, a subunit of the essential splicing factor 3b (SF3b) subcomplex in the spliceosome, and is required for correct P27Kip1 (P27) pre-mRNA splicing, after which P27 arrests cells in G1[8]. Third, SAP155 is required for correct FIR pre-mRNA splicing and thus the FIR/FIRΔexon2/SAP155 interaction bridged c-myc and p27 expression[9]. Accordingly, SAP155-mediated alternative splicing of FIR serves as a molecular switch for c-myc expression[9]. Finally, splicescan A (SSA), a natural SF3b inhibitor, markedly inhibited P27 expression by disrupting its pre-mRNA splicing and reducing cdk2/cyclinE expression[9]. Taken together, these findings suggest that exogenous FIR stimulates the FIR/FIRA exon2/SAP155 interaction which is pivotal for the cell cycle, cancer development and differentiation.

In this study, a fusion gene-deficient human FIR-expressing Sendai virus vector (SeV/dF/FIR) was prepared for future cancer therapy for the following reasons; Sendai virus (SeV), a member of the Paramyxoviridae family, has envelopes and a nonsegmented negative-strand RNA genome. The SeV genome contains six major genes in tandem on a single negative-strand RNA. Three proteins, the nucleoprotein (NP), phosphoprotein (P) and large protein (L; the catalytic subunit of the polymerase) form a ribonucleoprotein complex (RNP) with the SeV RNA. Matrix proteins (M) contribute to the assembly of viral particles, hemagglutinin-neuraminidase (HN) and fusion proteins (F) engage in the attachment of viral particles and infiltration of RNPs into infected cells. Importantly, SeV does not transform cells by integrating its genome into the cellular genome[10]. Therefore, SeV can mediate gene transfer and expression to a cytoplasmic location using cellular tubulin[11], thereby avoiding possible malignant transformation due to the genetic alteration of host cells. These are the safety advantages of SeV. Recently, a novel SeV vector was established where an enhanced green fluorescent protein (EGFP) reporter gene was inserted at the 3'-end of fusion gene-deficient SeV genomic RNA (SeV/dF/EGFP)[12]. This SeV/dF/EGFP is incapable of self-replication, but capable of infecting various cells, including human smooth muscle cells, hepatocytes, and endothelial cells, thus the SeV/dF/EGFP has a broad spectrum of gene transfer activity[13,14]. In this study, SeV/dF/FIR was prepared following the method for SeV/dF/EGFP[12,15]. The validity of SeV/dF/FIR for cancer therapy was examined in animal xenograft models as SeV/dF vectors have been shown to be applicable for clinical use[15-18]. The clinical use of SeV/dF/FIR for cancer therapy is also discussed.

MATERIALS AND METHODS

Plasmids

Full-length FIR cDNA (HA-FIR) was cloned into the pCGNM2 vector plasmid to introduce the hemagglutinin (HA)-tag at the amino termini[17]. Full-length FIR cDNA was cloned into the p3xFLAG-CMV-14 vector (Sigma, MO, United States) to introduce the Flag-tag at the amino termini for the selection of FIR-Flag in 293T cells (performed by Dr. T.N). Plasmids were prepared by...
CsCl ultra-centrifugation or the Endofree® Plasmid Maxi Kit (Qiagen, MD, United States) and the DNA sequences were verified.

**Tumor cell lines**

HeLa cells (human cervical squamous cell carcinoma cells), LoVo and SW480 cells (human colon cancer cell lines) and LLC-MK2 a rhesus monkey kidney cell line were purchased from the American Type Culture Collection (Manassas, VA, United States). Yes-5, a human esophageal squamous cell carcinoma cell line was established by Dr Takuo Murakami (Yamaguchi University, Yamaguchi, Japan). All cell lines were cultured at 37 ℃ in a humidified atmosphere containing 5% CO₂. All tumor cell lines, except LLC-MK2 cells [which were maintained in DMEM; Dulbecco’s Modified Eagle’s Medium (Gibco BRL, NY, United States)] were cultured in tissue flasks or Petri dishes containing RPMI-1640 (Gibco, NY, United States) supplemented with 10% heat-inactivated FBS and penicillin (100 units/mL), streptomycin (0.1 mg/mL), and 2 mmol/L glutamine.

**Immunocytochemistry, protein extraction and immunoblotting**

Immunocytochemistry was performed as described previously[7]. Protein extraction and immunoblotting are described elsewhere[8].

**siRNA against FIR or SAP155**

SAP155 siRNA duplexes were purchased from Sigma Aldrich. The target sequences for SAP155 siRNA oligonucleotides were listed previously[9]. Luciferase GL2 duplex was used as a negative control for siRNA targeting 5'-CGTACGCGGAATACTTCGA-3'. Transient transfection of siRNA was carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. The transfected cells were cultured for 72 h at 37 ℃ in 5% CO₂ incubator.

**Apoptosis detection**

Apoptotic cells were detected by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay according to the manufacturer’s instructions (Apoptosis Detection System, Fluorescein, Promega, WI, United States) as described previously[7]. Apoptosis detection by APOPercentage apoptosis assay™ (Funakoshi Co., Ltd., Tokyo, Japan) was performed according to the manufacturer’s instructions[8].

**Construction of SeV vector**

Human FIR cDNA was amplified with a pair of NotI site-tagged primers containing SeV-specific transcriptional regulatory signal sequences, (End and Start, italicized below) 5'-ATTTCGCGCGCCAGGTTCAATGGGC-3' and 5'-ATTTCGCGCGCGCATACCAGACC3'. The amplified fragment was introduced into the NotI site of the parental SeV vector cDNA, pSeV18+b(+)/dF[10], to generate pSeV18+b(H)+/dF. The pSeV18+b(H)+/dF/SeV was transfected to LLC-MK2 cells which were preliminarily infected with psoralen- and long-wave UV-treated vaccinia virus vTF7-3, expressing T7 polymerase. The cells were then washed twice with DMEM, and cultured for 24 h in DMEM containing cytosine β-D-arabinofuranoside (AraC; 40 μg/mL) and trypsin (7.5 μg/mL). LLC-MK2/F7/A cells expressing the F protein were suspended in DMEM containing AraC and trypsin, and layered onto the transfected cells, and cultured at 37 ℃ for an additional 48 h. The recovered vector in the culture supernatants was propagated using the LLC-MK2/F7/A cells. A GFP expression vector (SeV/dF/GFP) was prepared as previously described[10]. The viral vectors were further amplified by several rounds of propagation. The virus titers of the recovered vectors were determined by their infectivity and expressed using cell-infectious units (CIU). These vectors were frozen at -80 ℃ until use.

**SeV/dF/GFP-mediated green fluorescent protein transduction efficiency**

One million LLC-MK2 cells and HeLa cells were seeded in six-well plates and transduced with SeV/dF/GFP when monolayers reached 60%-80% confluence. As the standard inoculation procedure for vaccination, the monolayers were washed twice with PBS and overlaid with serum-free medium containing SeV/dF/GFP at a multiplicity of infection (MOI) of 0, 1, 10, 50, 100, or 300. After incubation at 37 ℃ for 90 min, non-adsorbed virus was removed, medium containing 10% FBS was added, and the cells were incubated for more than 48 h at 37 ℃. The transduction studies were carried out in triplicate for each MOI. Microscopy was used to detect transduced cells by GFP fluorescence. At 72 h after transduction, the GFP-transduced cells were analyzed for GFP expression using a FACS Calibrator (BD Pharmingen, Franklin Lakes, NJ, United States).

**MTS assay to assess cell viability**

The inhibitory effects of viruses on the proliferation of cultured cells were examined using the CellTiter96® AQueous One Solution Proliferation Assay (Promega, Madison, WI, United States). In brief, five thousand cells were plated in each well on day 0. On day 1, 24 h later, HeLa cells were infected with SeV/dF/FIR or SeV/dF/GFP as the control at 0.1 to 10 MOI, and cultured for 2 d. On day 3, cell viability was quantified by measuring the absorbance at 570 nm using the tetrazolium compound [3-(4,5-di-methylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS)], and an electron coupling agent, phenazine ethosulfate (PES) (Promega, Madison, WI, United States) for 4 h. The absorbance at 570 nm was measured by a Mutiabel Counter™, ARVOSX WAILACT™ (Perkin Elmer, MA, United States). The results are shown as percentages of the uninfected control cells.

**Mice**

Six- to eight-week male immuno-competent Balbc/nu/
nu mice were purchased from Clea Japan (Tokyo, Japan) and housed in the Animal Maintenance Facility at Chiba University under specific pathogen-free conditions. All animal experiments were approved by the Committee of the Ethics on Animal Experiments in the Faculty of Medicine, Chiba University and carried out following the Guidelines for Animal Experiments in the Faculty of Medicine, Chiba University, Chiba, Japan and The Law and Notification of the Government. Mouse experiments were carried out at least twice to confirm the results.

**Tumor xenograft experiments**

The *in vivo* inhibition of tumorigenicity of HeLa cells (human cervical squamous cell carcinoma cells) was examined by SeV/dF/FIR or SeV/dF/GFP injection (as the control). 5 × 10⁶ cells/50 μL PBS of HeLa cells were injected under the skin in the right thigh of nude mice (6-wk old males). Tumor growth was observed and the long and short diameter measured for tumor volume calculation. Thirty days after inoculation, tumors grew up to 5-8 mm in diameter in 18 of 18 mice (100%). Tumor size was calculated using the formula, \((a \times b)^{2}/2\), where a and b represent the larger and smaller diameters, respectively, and was monitored every 3 d.

**FIR-binding protein identification**

The methods for the direct nanoflow liquid chromatography-tandem mass spectrometry system with FIR-FLAG transiently transfected 293T nuclear extracts have been described previously[19-23].

**RESULTS**

**HA-FIR suppresses endogenous c-Myc expression with apoptosis induction in vivo**

To examine endogenous *c-myc* gene suppression by FIR, HA-FIR expression plasmids were transfected into HeLa cells, and c-Myc expression was visualized by immunostaining with anti-c-Myc antibodies (Figure 1A; upper panels: HA-FIR is red; c-Myc is green). c-Myc levels were greatly diminished in HA-FIR expressing cells (arrows), demonstrating that FIR represses endogenous c-Myc expression in SW480 (Figure 1A; middle panels) and LoVo cells (Figure 1A; lower panels). After HA-FIR expression plasmids were transfected into HeLa, SW480 or LoVo cells, apoptotic cells were visualized by TUNEL assay. HA-FIR transfected cells were definitively associated with apoptosis (Figure 1B).

**FIR protein expression by fusion gene-deficient SeV/dF/FIR**

SeV/dF/FIR and SeV/dF/GFP were prepared as described in Materials and Methods (Figure 2A, B). SeV/dF/FIR vectors were infected into LLC-MK2 or HeLa cells. FIR protein expression level was examined by western blot with anti-FIR antibody (6B4) (Figure 2C). At least 1 × 10⁸ CIU of fusion gene-deficient SeV/dF/FIR virus particles were prepared at amplification for use in the experiments.

**Transduction efficiency of the SeV/dF/GFP vector in various human tumor cell lines**

Nine human and five murine tumor cell lines plus non-tumor cells, propagated *in vitro* were collected, transduced by SeV/dF/GFP, and examined for gene transduction efficiency. Flow cytometric analyses showed dose-dependent GFP expression, and optimal expression was obtained at a MOI of 10-100; > 90% GFP-positive tumor cell lines were detected at a MOI over 10 (Figure 3A and data not shown). Furthermore, SeV/dF/FIR, but not SeV/dF/GFP significantly suppressed HeLa cell (human cervical squamous carcinoma) growth as shown by the APOPercentage assay (Figure 3B), indicating SeV/dF/FIR suppresses tumor cell growth by apoptosis *in vivo*.

**SeV/dF/FIR vector showed anti-tumor activity in the mouse xenograft model**

SeV/dF/FIR, but not SeV/dF/GFP, significantly suppressed cell growth in HeLa cells (Figure 4A) and SW480 cells when analyzed by Dunnet’s test for multiple comparisons (Figure 4B). Of note, xenograft tumors 2 cm in diameter disappeared completely following SeV/dF/FIR treatment, indicating that SeV/dF/FIR has immunological effects (Figure 5)[24,25].

**FIR was co-immunoprecipitated with SAP155**

If SeV/dF/FIR is to be tested clinically, endogenous FIR-interacting proteins should be identified to avoid unexpected side effects. For this purpose, the FIR-FLAG tag vector was transiently expressed in 293T cells and co-immunoprecipitated with anti-FLAG conjugated beads to detect FIR-binding proteins[26,27] (Table 1). As reported previously, FBP (Far upstream element-binding protein)[26,27], SAP155[28], and SRp54 (splicing factor, arginine/serine rich-12)[28] were identified as candidate FIR-binding proteins. To date, no significant side effects have been observed following SeV/dF/FIR treatment including our study[29].

**SeV/dF/FIR suppressed SSA-activated c-Myc**

We previously reported that the adenovirus vector encoding FIRAexon2 (Ad-FIRAexon2) activates not only *c-myc* transcription, but also c-Myc protein expression in HeLa cells[8]. However, the extent of c-Myc protein activation by Ad-FIRAexon2, evaluated by western blot analysis, could not be explained solely by *c-myc* transcription activation[8]. Therefore, we hypothesized that c-Myc protein should be modified by Ad-FIRAexon2 to be more stable. Ad-FIRAexon2 expression leads to increased levels of c-Myc phosphorylated at Ser62 (data not shown), indicating that stable c-Myc protein accumulates in cells[30,31]. As reported previously, SAP155 siRNA inhibited FIR pre-mRNA splicing and generated FIRAexon2[29]. In fact, SAP155 siRNA increased levels of c-Myc phosphorylated at Ser62 and Ad-FIRAexon2 (Figure 6A). In other words, Ad-FIRAexon2, which lacks the transcriptional repressor
Figure 1 Far up stream element-binding protein-interacting repressor suppresses endogenous c-Myc in SW480 and LoVo cells as well as HeLa cells. A: 100 fmol of HA-FIR was transfected into the colon cancer cell lines, SW480 and LoVo cells, as well as HeLa cells (cervical squamous cell carcinoma cells) in a 6-well plate. After 48 h transfection, cells were fixed and immunostained against c-Myc (left, green) or HA (middle, red) antibodies. Arrowheads (HeLa), thick arrows (SW480) and thin arrows (LoVo) show the cells in which HA-FIR plasmids were expressed. c-Myc expression (left, green) was markedly reduced in most HA-FIR-expressing cells (middle, red) (indicated by arrowheads and arrows); B: HA-FIR transfected cells were definitively associated with apoptosis as revealed by TUNEL assay in HeLa, SW480 and LoVo cells. Nuclear DNA was stained with DAPI (right, blue). FIR: FBP Interacting Repressor; FBP: FUSE-Binding protein; FUSE: Far Upstream Element.
domain, directly or indirectly activated c-myc expression not only through transcription, but also through protein level, suggesting that FIRΔexon2 acts in opposition to the repressor function by FIR\[8\].

In this study, the effect of SeV/dF/FIR was examined to determine whether it suppresses the increase in c-Myc after SSA treatment. SeV/dF/FIR suppressed SSA-induced c-Myc activation (Figure 6B, compare lane 2 with lane 1), but not basal c-Myc expression (Figure 6B, compare lanes 4 to 3 and 6 to 5, respectively). These results were consistent with previous reports that FIR suppresses activated, but not basal, c-myc transcription\[6\].

These observations suggest that the increase in c-myc by either SAP155 siRNA or SSA treatment is due to reduced FIR activity, or an increase in the ratio of FIRΔexon2/ F IR in HeLa cells. Taken together, these results suggest that SeV/dF/FIR is potentially clinically applicable for cancer therapy as it counteracts SSA-activated c-Myc (Figure 6B, compare lane 2 with lane 1) as well as endogenous c-Myc (Figure 1A).

**SeV/dF vector transduction**

F gene-deficient SeV vectors (SeV/dF) can transduce cells in a wide range of tissues such as respiratory, nervous, muscular, epithelial and immune tissues\[11,32-35\]. Transduction efficiency to cell lines from various tissues was examined and compared to the adenovirus vector expressing LacZ (Ad5/LacZ) at the same MOI. The transduction efficiency of SeV/dF to those cells was even higher than that of adenovirus vector (Figure 7).

**DISCUSSION**

Overexpression of c-Myc has been known to promote...
cell growth, proliferation and immortalization, whereas a reduction in c-Myc induces apoptosis. The recent genetic construction of the mouse in which the expression of c-myc can be switched on or off in vivo has emphasized the significance of c-Myc expression in tumorigenesis. Ectopic c-myc expression in hematopoietic cells using the tetracycline regulatory system caused malignant T cell lymphomas and acute myeloid leukemia; subsequent inactivation of the transgene caused regression of established tumors\[36\]. These observations have provided encourage-
The relative suppression ratio
SeV/dF/FIR: SeV/dF/GFP (%)

0                   0.1                    1                  10
MOI

P = 0.0007

40
30                        60                      90                    120
Day after Yes-5 cells xenograft (d)

10
8
6
4
2
0

Day 0                                              Day 14                                          Day 90                                               Day 140

Tumor volume × 10^3 (mm^3)

3.0 × 10^7 CIU each of SeV/dF/FIR injection for total even times

Figure 5 Sendai virus/dF/Far up stream element-binding protein-interacting repressor vector showed anti-tumor activity in a mouse xenograft model. 10^7 Yes-5 cells were xenografted into the right thigh of Balbc/nu/nu mice, and the tumor size was approximately 15 mm in diameter at Day 0. 3.0 × 10^7 CIU of SeV/dF/FIR vectors were injected directly around the tumor every two days, seven times in total. Tumor growth was observed and measured every two days as described in Materials and Methods. Ulcer formation was observed in the center of the tumor (day 14 after SeV/dF/FIR injection). Tumor size was significantly diminished with ulcer formation (day 90) and disappeared completely during surveillance (day 140). Thick arrows in the images indicate the tumor margin. Thin arrows indicate the injection of SeV/dF/FIR vectors into the tumor. FIR: FBP Interacting Repressor; FBP: FUSE-Binding protein; FUSE: Far Upstream Element; SeV: Sendai virus; CIU: Cell-infectious units.

Figure 4 Sendai virus/dF/Far up stream element-binding protein-interacting repressor decreased HeLa cell growth in vitro and in a xenograft animal model. HeLa cells (A) and SW480 cells (B) were infected with 0, 0.1, 1, and 10 MOI of SeV/dF/FIR or SeV/dF/GFP vectors and cell growth was measured by MTS assay (see Materials and Methods). Results are shown as the percentage of cell number at day 0. Points, mean of three separate experiments; bars, SD. Statistical significance was analyzed by Dunnett’s test for multiple comparisons (SeV/dF/FIR vs SeV/dF/GFP, P < 0.007). Two weeks after 5 × 10^6 HeLa cells were xenografted into the right thigh of Balbc/nu/nu mice, the tumor size was approximately 7-8 mm. 3.0 × 10^7 CIU of SeV/dF/FIR or SeV/dF/GFP vector were injected directly around the tumor, and the tumor growth was observed and measured every three days as described in Materials and Methods. Results are shown as the ratio of tumor volume compared to the size at day 0. Tumor volume at day 0 of SeV/dF/FIR (n = 6), SeV/dF/GFP (n = 5), and control (n = 5) were 1173.1 ± 259.2, 836.0 ± 259.2, and 972.2 ± 327.0 (average ± SD) mm^3, respectively. The average tumor volume at day 0 was estimated as 1 in each experiment. Arrows indicate the injection of SeV/dF/FIR or SeV/dF/GFP vectors. FIR: FBP Interacting Repressor; FBP: FUSE-Binding protein; FUSE: Far Upstream Element; SeV: Sendai virus; GFP: Green fluorescent protein; MOI: Multiplicity of infection.

Matsushita K et al. FIR-encoding Sendai virus vector for cancer gene therapy
| Hit preys                                      | Matsuhashita K et al. FIR-encoding Sendai virus vector for cancer gene therapy |
|-----------------------------------------------|--------------------------------------------------------------------------------|
| CDKN2AIP                                      | CDKN2A interacting protein                                                      |
| CDYL                                          | Chromodomain protein, Y chromosome-like                                         |
| DAZAP1                                        | DAZ associated protein 1                                                       |
| DDX17                                         | DEAD box polypeptide 17                                                        |
| DDX5                                          | DEAD (Asp-Glu-Ala-Asp) box polypeptide 5                                       |
| ELAVL1                                        | ELAV-like 1                                                                   |
| FAM120A                                       | Oxidative stress-associated Src activator                                      |
| FUBP1 | FUBP3 | KHSRP                          | Far upstream element-binding protein family                                    |
| HNRNPA1                                       | Heterogeneous nuclear ribonucleoprotein A1                                    |
| HNRNPA1 | HNRNPA1L2 | LOC402562 | Heterogeneous nuclear ribonucleoprotein A1 family                              |
| HNRNPA2B1                                     | Heterogeneous nuclear ribonucleoprotein A2/B1                                 |
| HNRNPA3                                       | Heterogeneous nuclear ribonucleoprotein A3                                    |
| HNRNPA8                                       | Heterogeneous nuclear ribonucleoprotein A1/B; isoform a                        |
| HNRNPD                                        | Heterogeneous nuclear ribonucleoprotein; A/B or D                             |
| HNRNPH1                                       | Heterogeneous nuclear ribonucleoprotein D                                     |
| HNRNPK                                        | Heterogeneous nuclear ribonucleoprotein K                                     |
| HNRNPL                                        | Heterogeneous nuclear ribonucleoprotein L                                    |
| HNRNPM                                        | Heterogeneous nuclear ribonucleoprotein M; isoform a                          |
| HNRNPR                                        | Heterogeneous nuclear ribonucleoprotein R                                    |
| HNRNPU                                        | Heterogeneous nuclear ribonucleoprotein U; isoform a                          |
| HNRNPU1                                       | Heterogeneous nuclear ribonucleoprotein U-like 1                              |
| HNRNDDL                                       | Heterogeneous nuclear ribonucleoprotein D-like                                |
| IFT5                                          | Interferon-induced protein with tetrapeptide repeats 5                        |
| IGF2BP1                                       | Insulin-like growth factor 2 mRNA binding protein 1                            |
| IGF2BP1 | IGF2BP3 | KHSRP                          | Insulin-like growth factor 2 mRNA binding protein 1; or 1 or 3                  |
| IGF2BP2                                       | Insulin-like growth factor 2 mRNA binding protein 2                            |
| IGF2BP3                                       | Insulin-like growth factor 2 mRNA binding protein 3                            |
| ILF2                                          | Interleukin enhancer binding protein factor 2                                 |
| KHDRBS1                                       | KH domain containing, RNA binding, signal transduction associated 1           |
| KHDRBS1 | KHDRBS2 | KHDRBS3 | KH domain containing, RNA binding, signal transduction associated 1           |
| KHDRBS1 | KHDRBS2 | KHDRBS3 | KH domain containing, RNA binding, signal transduction associated 1           |
| KHSRP                                         | KH-related protein                                                            |
| KIAA1967                                      | p30 DRC protein                                                               |
| LARP1                                         | La related protein                                                            |
| LRP2RC                                        | Leucine-rich PPR motif-containing protein                                       |
| LSM12                                         | LSM12 homolog                                                                 |
| MAGOH1 | MAGOHB | MATR3                           | Mago-nashi homolog; or B                                                      |
| MATR3                                         | Matrin 3                                                                      |
| MOV10                                         | Mov10, Moloney leukemia virus 10, homolog                                       |
| MS2                                           | Musashi 2; isoform a                                                           |
| PABP3 | PABPC1 | PABPC3                          | Poly (A) binding protein, cytoplasmic 1                                        |
| PABPC1 | PABPC1L | PABPC5                          | Poly (A) binding protein, cytoplasmic 1 or poly(A)-binding protein,            |
| PABPC1 | PABPC4                          | Poly (A) binding protein, cytoplasmic 1 or poly(A)-binding protein,            |
| PABPC1L2B | PABPC4                          | Poly (A) binding protein, cytoplasmic 1 or poly(A)-binding protein,            |
| PABPC4                                        | Poly (A) binding protein, cytoplasmic 1 or poly(A)-binding protein,            |
| PABPC4L                                       | Poly (A) binding protein, cytoplasmic 1 or poly(A)-binding protein,            |
| PABPN1                                        | Poly (A) binding protein, nuclear 1                                            |
| PCBP2 | PCBP3                          | Poly (C) binding protein, or 1 or 2 or 3 or 4                                 |
| PCBP2 | PCBP3                          | Poly (C) binding protein, or 1 or 2 or 3 or 4                                 |
| PTBP1                                         | Poly (C) binding protein, or 1 or 2 or 3 or 4                                 |
| SF3B1                                         | Splicing factor 3B, subunit 1                                                  |
| SF3B4                                         | Splicing factor 3B, subunit 3                                                  |
| SF3B4                                         | Splicing factor 3B, subunit 4                                                  |
| SFQP                                          | Splicing factor proline/glutamine rich (polyprolineimidine tract binding       |
| SFQP                                          | Splicing factor, arginine/serine-rich 11 (SBrp54)                              |
| SFQP                                          | Splicing factor, arginine/serine-rich 12                                      |
| SNRPD1                                        | Small nuclear ribonucleoprotein D1 polypeptide 16 kDa                         |
| SSb                                           | Autoantigen La                                                                |
| SYNCRIP                                       | Synaptotagmin binding, cytoplasmic RNA interacting protein                    |
ment for the future development of cancer therapies based on targeting individual oncogenes such as *c-myc*. We have previously reported that FIR strongly represses endogenous *c-myc* transcription, and induces apoptosis and is thus applicable for cancer treatment. In this study, first, we demonstrated that *c-myc* suppressor FBP-interacting repressor (FIR) strongly repressed endogenous *c-myc* transcription and induced apoptosis in SW480, LoVo (human colon cancer cell lines) as well as HeLa cells (human cervical squamous cancer cell line). Second, SeV/dF/FIR showed strong anti-tumor effects in both cultured cells and xenograft tumor growth in an animal model. These results provide new insight into a new therapeutic target for tumor treatment.

What type of suitable vector should be selected and how should FIR expressing vectors be conveyed to cancers? Sendai virus is an RNA virus and exists only in the cytoplasm, hence it is relatively safe as it does not affect chromosomes. In addition, SeV does not transform cells by integrating its genome into the cellular genome, thereby avoiding possible malignant transformation due to the genetic alteration of host cells; this is a safety advantage of SeV. For this reason, we chose SeV and prepared a fusion gene-deficient SeV/dF/FIR vector. The fusion gene-deficient SeV vector cannot transmit to F protein-non-expressing cells as F protein is essential for viral infection. The fusion gene-deficient SeV vector in this study does not require helper virus for reproduction, but is self-replicable in infected cells. Thus, the fusion gene-deficient SeV vector shows highly efficient gene transfer to a wide spectrum of cells, even to smooth muscle cells, nerve cells, or endothelial cells which are generally difficult to infect. Fourth, the SeV vector shows highly efficient gene transfer to a wide spectrum of cells, even to smooth muscle cells and does not generate wild-type virus in packaging cells. Recently, a gene-deficient SeV (SeV/dF) vector alone demonstrated tumor suppression by activating dendritic cells (DCs)\(^\text{[24]}\), or if granulocyte

---

**Figure 6** SAP155 siRNA induces c-Myc activation with Erk phosphorylation, but suppresses phosphorylated-cdk2/cyclinE expression. HeLa cells were treated with SAP155 siRNA for three days (72 h). A: SAP155 siRNA, as well as SSA treatment, increased not only c-Myc expression level, but also c-Myc phosphorylation at both Ser62, but suppressed phosphorylated-cdk2 and cyclinE in a dose-dependent manner. Thus, SAP155 siRNA activates c-Myc potentially via inhibiting endogenous FIR premRNA splicing; B: FIR Sendai virus (SeV/dF/FIR) reversed the cytotoxicity of SSA by suppressing activated endogenous c-Myc. HeLa cells were treated with 50 ng/mL SSA for 48 h with control (MetOH and H\(_2\)O).

**Legend:**

- **A**: SAP155 siRNA, as well as SSA treatment, increased not only c-Myc expression level, but also c-Myc phosphorylation at both Ser62, but suppressed phosphorylated-cdk2 and cyclinE in a dose-dependent manner. Thus, SAP155 siRNA activates c-Myc potentially via inhibiting endogenous FIR premRNA splicing.
- **B**: FIR Sendai virus (SeV/dF/FIR) reversed the cytotoxicity of SSA by suppressing activated endogenous c-Myc. HeLa cells were treated with 50 ng/mL SSA for 48 h with control (MetOH and H\(_2\)O). 10 MOI of SeV/dF/FIR apparently suppressed activated c-Myc expression, whereas SeV/dF/FIR did not influence basal expression (MetOH or H\(_2\)O). FIR: FBP Interacting Repressor; FBP: FUSE-Binding protein; FUSE: Far Upstream Element; SeV: Sendai virus; GFP: Green fluorescent protein; MOI: Multiplicity of infection; SSA: Spliceostatin.
macrophage colony-stimulating factor was encoded, it produced autologous tumor vaccines\(^{[25]}\). Therefore, the SeV/dF/FIR vector in this study may suppress tumor growth by a dual function through c-Myc suppression of tumor cells and DC activation. Furthermore, SeV/dF/FIR showed a synergistic effect with cisplatin in the treatment of malignant pleural mesothelioma\(^{[29]}\). FIR-binding proteins are basically classified into four categories (Table 1); (1) RNA binding proteins and splicing factors; (2) transcription factors and chromatin remodeling proteins; (3) actin-binding proteins; and (4) signal transduction and protein kinase families. This suggests that FIR potentially engages in some different intracellular events, such as RNA transport, DNA damage repair and pre-mRNA splicing. Accordingly, the side effects of SeV/dF/FIR need to be considered before clinical use, such as pre-mRNA splicing disturbance\(^{[8,9]}\), DNA damage repair\(^{[37]}\) or intracellular protein transport interference. For clinical safety, SeV/dF/FIR is preferable for local tumor growth control rather than systemic cancer therapy.

Taken together, these findings show that SeV/dF/FIR is a promising approach for cancer gene therapy, although further clinical and basic research are required to explain the precise mechanism of tumor suppression by FIR expressing vectors.

ACKNOWLEDGMENTS

The authors thank to Dr. David Levens (NCI, NIH, United States) for scientific discussions, Dr. Tohru Natsume (Biomedicinal Information Research Center, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan) for FIR-binding proteins analysis, and Dr. Minoru Yoshida (Chemical Genetics Laboratory, RIKEN Advanced Science Institute, Saitama, Japan) for the kind gift of Spliceostatin A (SSA).

COMMENTS

Background

Far Up Stream Element-Binding Protein-Interacting Repressor (FIR) is a c-myc transcriptional repressor. Thus, FIR expressing vectors are applicable for cancer therapy. In this study, the authors examined a novel therapeutic strategy to suppress c-myc in human cancers using a fusion gene-deficient Sendai virus (SeV/dF/FIR) which is inherently non-transmissible.
Research frontiers
As c-myc transcriptional control is largely unknown, modulation of c-myc regulation by SeV/dF/FIR for cancer therapy should be monitored, strictly and skeptically, from several aspects. This study revealed that SeV/dF/FIR is effective for cancer therapy without significant side effects in a xenograft model.

Innovations and breakthroughs
SeV/dF/FIR showed high gene transduction efficiency with significant antitumor effects and apoptosis induction in HeLa and SW480 cells. In the xenograft model, SeV/dF/FIR showed strong suppression of tumor growth with no significant side effects.

Applications
SeV/dF/FIR is potentially applicable for future clinical cancer treatment as SeV/dF/FIR suppresses endogenous c-Myc as well as Spliceostatin A (SSA)-activated c-Myc.

Terminology
FUSE: Far Upstream Element which is required for correct c-myc transcription.
FPRP: FUSE-Binding protein which has strong transcriptional activity. FPRP: FPRP interacting repressor which is a critical transcriptional repressor of c-myc gene.
SeV: Sendai virus, a member of the Paramyxoviridae family, has envelopes and a nonsegmented negative-strand RNA genome. The SeV genome contains six major genes in tandem on a single negative-strand RNA. DC: Dendritic cell.
The gene-deficient SeV (SeV/dF) vector alone demonstrates tumor suppression by activating dendritic cells (DCs).

Peer review
The authors performed the enthusiastic experiments in vivo and animal model to examine the SeV/dF/FIR for cancer gene therapy to minimize the side effect for the clinical use.

REFERENCES
1. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002; 109: 321-334 [PMID: 12015982 DOI: 10.1016/S0092-8674(02)00738-9]
2. Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A, Komatsu A, Matsubara H, Ochiai T. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma in situ. Cancer Sci 2006; 97: 57-63 [PMID: 16367922 DOI: 10.1111/j.1349-7006.2006.00137.x]
3. Avigan MI, Strober B, Levens D. A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem 1990; 265: 18538-18545 [PMID: 2221718]
4. Bazar L, Meighen D, Harris V, Duncan R, Levens D, Avigan M. Targeted melting and binding of a DNA regulatory element by a transactivator of c-myc. J Biol Chem 1995; 270: 8241-8248 [PMID: 7713951 DOI: 10.1074/jbc.270.14.8241]
5. Micheielli GA, Micheielli EF, Pullner A, Duncan RC, Eick D, Levens D. Multiple single-stranded cis elements are associated with activated chromatin of the human c-myc gene in vivo. Mol Cell Biol 1996; 16: 2656-2669 [PMID: 8649573]
6. Liu J, Aukulitchie S, Weber A, Ge H, Chukiov S, Libutti D, Wang XW, Conaway JW, Harris CC, Conaway RC, Reinberg D, Levens D. Defective interplay of activators and repressors with TFIIH in xeroderma pigmentosum. Cell 2001; 104: 535-363 [PMID: 11239393 DOI: 10.1016/S0092-8674(01)00225-9]
7. Matsushita K, Tomonaga T, Shimada H, Shioya A, Hagish A, Matsubara H, Harigaya K, Nomura F, Libutti D, Levens D, Ochiai T. An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis. Cancer Res 2006; 66: 1409-1417 [PMID: 16452196 DOI: 10.1158/0008-5472.CAN-04-4459]
8. Matsushita K, Kajiwara T, Tomonaga M, Satoh M, Tanaka N, Tomonaga T, Matsubara H, Shimada H, Yoshimoto R, Ito K, Aku S, Natsume T, Levens D, Yoshida M, Nomura F. SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression. Mol Cancer Res 2012; 10: 787-799 [PMID: 22494641 DOI: 10.1158/1541-7786.MCR-11-0462]
9. Matsushita K, Tamura M, Tanaka N, Tomonaga T, Matsubara H, Shimada H, Levens D, He L, Liu J, Yoshida M, Nomura F. Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression. Mol Cancer Res 2013; 11: 689-698 [PMID: 2359476 DOI: 10.1158/1541-7786.MCR-12-0673]
10. Kaida D, Motoyoshi H, Tashiro E, Nijima T, Hagiwara M, Ishigami K, Watanabe H, Kitahara T, Yoshida T, Nakajima H, Tani T, Horinouchi S, Yoshida M. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007; 3: 376-385 [PMID: 17643111 DOI: 10.1038/nchembio.2007.18]
11. Li HO, Zhu YF, Asakawa M, Kuma H, Hirata T, Ueda Y, Lee YS, Fukumura M, Iida A, Kato A, Nagai Y, Hasegawa M. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with effective gene transfer and expression. J Virol 2000; 74: 6564-6569 [PMID: 10864670 DOI: 10.1128/JVI.74.14.6564-6569.2000]
12. Hirata T, Iida A, Shiraki-Iida T, Kitazato K, Kato A, Nagai Y, Hasegawa M. An improved method for recovery of F-defective Sendai virus expressing foreign genes from cloned cDNA. J Virol Methods 2002; 104: 125-133 [PMID: 12088822 DOI: 10.1016/S1056-6567(02)00044-7]
13. Mitomo T, Griesenbach U, Inoue M, Somerton L, Meng C, Akiba E, Tabata T, Ueda Y, Frankel GM, Farley R, Singh C, Chan M, Munkonge F, Bruen A, Xenarios I, Escudero-Garcia S, Hasegawa M, Altom EW. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther 2010; 18: 1173-1182 [PMID: 20332767 DOI: 10.1038/mt.2010.13]
14. Ueda Y, Hasegawa M, Yokomitsu Y. Sendai virus for cancer immunotherapy. Methods Mol Biol 2009; 515: 299-308 [PMID: 19578123 DOI: 10.1007/978-1-59745-559-6_21]
15. Tanaka M, Shimbo T, Kikuchi Y, Matsuda M, Kaneda Y. Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int J Cancer 2010; 126: 1982-1991 [PMID: 19830690]
16. Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer 2009; 124: 2478-2487 [PMID: 19173282 DOI: 10.1002/ijc.24234]
17. Kinoh H, Inoue M, Komaru A, Ueda Y, Hasegawa M, Yokomitsu Y. Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. Gene Ther 2009; 16: 392-403 [PMID: 19037241 DOI: 10.1038/gt.2008.167]
18. Kinoh H, Inoue M. New cancer therapy using genetically engineered oncolytic Sendai virus vector. Front Biosci 2008; 13: 2327-2334 [PMID: 17981715 DOI: 10.2741/2847]
19. Tomonaga T, Levens D. Heterogeneous nuclear ribonucleoprotein protein K is a DNA-binding transactivator. J Biol Chem 1995; 270: 4875-4881 [PMID: 7876260 DOI: 10.1074/jbc.270.9.4875]
20. Mizushima N, Kuma A, Kobayashi Y, Yamamoto A, Matsubae M, Takao T, Natsume T, Ohsumi Y, Yoshimori T. Mouse Agpl6L1, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Agpl2-Agpl5 conjugate. J Cell Sci 2003; 116: 1679-1688 [PMID: 12665549 DOI: 10.1242/jcs.00381]
21. Yanagida M, Hayano T, Yamauchi Y, Shinkawa T, Natsume T, Isobe T, Takahashi N. Human fibrillin forms a sub-complex with splicing factor 2-associated p32, protein arginine methyltransferases, and tubulins alpha 3 and beta 1 that is independent of its association with prerinosomal ribonucleoprotein complexes. J Biol Chem 2004; 279: 1607-1614 [PMID: 14585625 DOI: 10.1074/jbc.M306142200]
22. Natsume T, Yamauchi T, Nakayama H, Shinkawa T, Yanagida M, Takahashi N, Isobe T. A direct nanoflow liquid chroma-
molecular sensor for bleomycin-induced DNA damage pathway.

J Biol Chem 2009; 284: 630-639 [PMID: 18974054 DOI: 10.1074/jbc.M805395200]

Page-McCaw PS, Amorin-Lvidman K, Sharp PA. PUFP60: a novel U2AF65-related splicing activity. RNA 1999; 5: 1548-1560 [PMID: 10660266 DOI: 10.1017/S135583829991938]

Kitamura A, Matsushita K, Takiguchi Y, Shimada H, Tada Y, Yamanaka M, Hiroshima K, Tagawa M, Tomonaga T, Matsubara H, Inoue M, Hasegawa M, Sato Y, Levens D, Tatsumi K, Nomura F. Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malig-
nant pleural mesothelioma. Cancer Sci 2011; 102: 1366-1373 [PMID: 21435101 DOI: 10.1111/j.1349-7006.2011.01931.x]

Junttila MR, Wessnerman J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle 2008; 7: 592-596 [PMID: 18296542 DOI: 10.4161/cc.7.5.5492]

Lee T, Yao G, Nevins J, You L. Sensing and integration of Erk and PI3K signals by Myc. PLoS Comput Biol 2008; 4: e1000103 [PMID: 18463697 DOI: 10.1371/journal.pcbi.1000103]

Yonemitsu Y, Kitson C, Ferrari S, Farley R, Griesenbach U, Judd D, Steel R, Scheid P, Zhu J, Jeffery PK, Kato A, Hasan MK, Nagai Y, Masaki I, Fukumura M, Hasegawa M, Geddes DM, Altom EW. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18: 970-973 [PMID: 10973218 DOI: 10.1038/79643]

Inoue M, Tokusumi Y, Ban H, Shirakura K, Kanaya T, Yoshizaki M, Hironaka T, Nagai Y, Iida A, Hasegawa M. Recombinant Sendai virus vectors deleted in both the matrix and the fusion genes: efficient gene transfer with preferable properties. J Gene Med 2004; 6: 1069-1081 [PMID: 15386740 DOI: 10.1002/jgm.597]

Shirakura M, Inoue M, Fujikawa S, Washizawa K, Komaba S, Maeda M, Watabe K, Yoshikawa Y, Hasegawa M. Postischemic administration of Sendai virus vector carrying neurotrophic factor genes prevents delayed neuronal death in gerbils. Gene Ther 2004; 11: 784-790 [PMID: 14961067 DOI: 10.1038/sj.gt.3302224]

Okano S, Yonemitsu Y, Nagata S, Sata S, Onimaru M, Nakagawa K, Tomiya Y, Kishihara K, Hashimoto S, Nakashima Y, Sugimachi K, Hasegawa M, Sueishi K. Recombinant Sendai virus vectors for activated T lymphocytes. Gene Ther 2003; 10: 1381-1391 [PMID: 1288335]

Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4: 199-207 [PMID: 10488335 DOI: 10.1016/S1097-2765(00)80368-6]

Rahmutulla B, Matsushita K, Satoh M, Seimiya M, Tsuchida S, Kubo S, Shimada H, Otsuka M, Miyazaki M, Nomura F. Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway. Oncotarget 2013; December 21

P- Reviewer: Takenaga K  S- Editor: Ma YJ
L- Editor: Webster JR  E- Editor: Zhang DN
